Is it time to consider glaucoma screening cost-effective?

Lancet Glob Health. 2019 Nov;7(11):e1490. doi: 10.1016/S2214-109X(19)30395-X.

Authors

Piotr Kanclerz¹, Andrzej Grzybowski², Raimo Tuuminen³

Affiliations

¹ Hygeia Clinic, Gdańsk, Poland.
² Department of Ophthalmology, University of Warmia and Mazury, Olsztyn, Poland.
³ Institute for Research in Ophthalmology, Foundation for Ophthalmology Development, Poznań, Poland; Helsinki Retina Research Group, Faculty of Medicine, University of Helsinki, Helsinki 00014-HY, Finland; Eye Centre, Kymenlaakso Central Hospital, Kotka, Finland. Electronic address: raimo.tuuminen@helsinki.fi.

PMID: 31607458
DOI: 10.1016/S2214-109X(19)30395-X

No abstract available

Publication types

Letter
Comment

MeSH terms

China
Cost-Benefit Analysis
Glaucoma*
Humans
Mass Screening*